

GENART Technologies, Inc.

- The Art of Caring -

Harry F. Crevecoeur, M.D.

Valley Stream, NY 11580

Email: HCrevecoeurMD1@Genart.net

November 30, 2009

President Barack Obama
First Lady Michelle Obama
The White House
1600 Pennsylvania Ave., NW
Washington, DC 20500
(202) 456-1414

Re: The Ideal HIV Vaccine

Dear Mr. President and First Lady:

On behalf of my colleagues at Genart Technologies, I commend you both for the health care initiatives that you are pursuing to improve the lives of all Americans, as well as the global community. Since 1992, I have worked as an HIV specialist in Brooklyn, NY, caring for hundreds of patients who face the physical and emotional ravages, as well as the stigma, associated with HIV/AIDS. In 2003, I launched Genart Technologies in order to develop an HIV vaccine that would not be controlled by financial investment obligations.

I am pleased to inform you that as of August 1st 2007, at Genart Technologies, we have discovered **promising evidence that the HIV pandemic can be solved** with an ideal HIV vaccine that we designed to be: effective (with cross-clade neutralization of HIV-1), safe, therapeutic and preventative. Moreover our development strategies are aimed to keep this vaccine affordable. Despite limited funding, our novel HIV vaccine design enabled us to triumph where pharmaceutical giants like SmithKline-Beacham, Merck and others have either failed or given up. Although I respect any skepticism which may dominate your impressions at this time, **please allow me to invite you to accept the notion that, yes, a “CURE” for HIV is indeed possible -- and now finally in sight.** Contrary to recent inclinations on the HIV subject, we feel that this is no time to be complacent in our search for a “cure”.

By translating the conserved entity of HIV’s gp120 from 3-D configuration to linear formats, we helped conquer the most challenging issues in HIV vaccine design: broad-spectrum coverage with inter- and intra-clade neutralization of HIV-1.... As complex as it may sound, I submit to you that our method and our vaccine design hold the most promising solution to the HIV problem. I am confident that our HIV vaccine design, with your support, can succeed **in less than five years** and deliver the ground-breaking vaccine so desperately anticipated in the world.

We would like the opportunity to provide you and your trusted doctors/scientists more detailed information on our HIV vaccine and development strategies. Though yet unpublished, our information is covered by U.S. and international patents. We can arrange a conference at your convenience to demonstrate our interesting findings.

In our commitment to keep the final price of this life-saving vaccine affordable, we are seeking a collaborative agreement with the NIH to help finalize the pre-clinical studies and complete the clinical trials. We humbly ask if you would join your voice to our efforts and help make this “impossible dream” a reality soon.

As you know, the world depends greatly on American ingenuity: When “The Impossible” is actually “What needs to be done,” we get it done. We can do this. “*Yes we can!*”

Sincerely,

Harry F. Crevecoeur, MD
GENART Technologies, Inc.

CC: Former President Bill Clinton

Enclosures: